Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

EULAR/Other

ACR Pushes for Patient Interests, Against Spending Cuts

Angus Worthing, MD, FACP, FACR  |  July 5, 2017

Greetings from Washington, D.C. Your advocacy team had another busy month. Unlike my prior updates, and in order to keep our focus on health policy, I avoid mentioning anything about Washington investigations into obstruction of justice, collusion, etc. You get enough of that elsewhere. The Healthcare Bill Obamacare repeal and reform efforts are speeding up….

Comparative Assessment of the Different ACR/EULAR Remission Definitions for RA for Their Use as Clinical Trial End Points

Arthritis & Rheumatology  |  February 28, 2017

Significant advances have been made in the treatment of RA over the past 20 years, and with the hope of developing even more effective therapeutics, achieving a very low level of disease activity, such as remission, is an important outcome to be examined. The ACR and EULAR have defined remission using Boolean- or index-based criteria. The researchers undertook this study to compare definitions of remission to inform choice of end points for future RA clinical trials and included in their comparison the remission criterion of a score of ≤2.8 on the Clinical Disease Activity Index…

Updated EULAR Recommendations for Early Arthritis; Plus FDA Approves New Abuse-Deterrent Morphine Sulfate

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2017

EULAR has updated its recommendations for the management of early arthritis, outlining aspects of diagnosis and drug treatments…

First Non-Rheumatologist Health Professional Attends the ACR/EULAR International Exchange Program

Carol Patton  |  December 13, 2016

This past June, Yvonne Golightly, PT, MS, PhD, helped launch an international group of researchers focused on foot and ankle osteoarthritis. At the time, Dr. Golightly, an assistant professor in the department of epidemiology at the University of North Carolina (UNC), Chapel Hill, N.C., was attending the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)…

ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome

Kathy Holliman  |  November 15, 2016

Classification criteria for primary Sjögren’s syndrome (SS) have been approved by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), validating an international set of classification criteria for SS using standards set by both organizations. Those criteria can now be found in the 2016 ACR/EULAR Classification Criteria for Primary Sjögren’s Syndrome: A…

The ACR’s Collaboration with International Rheumatology Associations Promotes Progress

Joan M. Von Feldt, MD, MSEd, FACR, FACP, & Elizabeth A. Schlenk, PhD, RN  |  June 12, 2016

More than 10 years ago, New York Times journalist Thomas Friedman opined an old-world perspective that the world is, in fact, flat. In an article published on April 3, 2005, Mr. Friedman contended that “Individuals must, and can, now ask: Where do I fit into the global competition and opportunities of the day, and how…

New Gout Criteria from the ACR/EULAR Focus on Clinical Trials, Global Standards

Susan Bernstein  |  November 17, 2015

Gout affects nearly 4% of American adults, causing joint inflammation, pain and crystal deposits that may lead to bone erosion over time. At least five different classification criteria for gout are used worldwide, creating potential discrepancies in clinical trial enrollment and eventual results. An international panel of investigators collaborated to create new, standardized gout classification…

EULAR 2015: RA Research Shows Imperfect Guidelines, Suggests Strategies with Biologics

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks came…

EULAR 2015: Biology of Fatigue Rooted in Genes, Cytokines, Free Radicals

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Fatigue, a problem experienced frequently by patients with rheumatic diseases, is best thought of as a survival mechanism and as a single phenomenon, not a condition that comes in a variety of forms, an expert said in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Gene Regulated…

Phase 3 Studies Evaluate Lesinurad for Gout Treatment

Michele B. Kaufman, PharmD, BCGP  |  July 15, 2015

For 12 months, two studies examined the use of lesinurad in combination with allopurinol to treat gout, with patients achieving reduced serum uric acid levels and demonstrating no severe toxicity.

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences